Why the study?
Studies on the prevalence and determinants of resistant hypertension in patients with higher BMI values are limited, and the prevalence under the 2017 hypertension guidelines is unknown.
Based on the 2017 ACC/AHA guidelines, true resistant hypertension is present in 6.7% of high-risk overweight and obese patients and is associated with higher BMI, black race, insulin-requiring diabetes, CKD stage ≥3, and diastolic heart failure.
Answers are grounded in this paper and cite their sources.
May support out-of-office BP confirmation to identify true RH in obese patients; leaves open whether risk-factor associations improve targeted management.
Obesity is significantly associated with uncontrolled blood pressure and resistant hypertension (RH). There are limited studies on the prevalence and determinants of RH in patients with higher body mass index (BMI) values. Since the hypertension guidelines changed in 2017, the prevalence of RH has become unknown and now is subject to be estimated by further studies. We conducted a cross-sectional study in an urban Federally Qualified Health Center in New York City aiming to estimate the prevalence of RH in high-risk overweight and obese patients based on the new hypertension definition, BP threshold ≥130/80 mm Hg, and also to describe the associated comorbid conditions in these patients. We identified 761 eligible high-risk overweight and obese subjects with hypertension between October 2017 and October 2018. Apparent treatment-RH was found in 13.6% among the entire study population. This represented 15.4% of those treated with BP-lowering agents. True RH confirmed with out-of-office elevated BP was found in 6.7% of the study population and 7.4% among patients treated with BP-lowering agents. Prevalence was higher with higher BMI values. Those with true RH were more likely to be black, to have diabetes mellitus requiring insulin, chronic kidney disease stage 3 or above and diastolic heart failure. In conclusion, obesity is significantly associated with RH and other significant metabolic comorbid conditions.
No takes yet. Share an insight, caveat, or question.
Haddadin et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: